Navigation Links
Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update
Date:11/2/2010

calculation-- basic and diluted

22,964,2791,520,87519,567,0581,498,108ANTHERA PHARMACEUTICALS, INC.A Development Stage CompanyBALANCE SHEET DATA(unaudited)September 30,
2010December 31,
2009Cash and cash equivalents

$
51,208,720$
3,803,384Short term investments

$
21,878,890Total assets

$
74,923,205$
5,888,789Total notes payable

$
8212;$
3,129,877Total warrant and derivative liabilities

$
8212;$
406,130Total current liabilities

$
4,837,707$
8,167,645Deficit accumulated during development stage

$  (92,603,647)$  (65,229,952)Total shareholders' equity (deficit)

$
70,085,498$  (12,278,856)Common shares outstanding

32,796,6901,566,199Preferred shares outstanding

—8,146,308
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Anthera Announces Third Quarter 2010 Financial Report and Conference Call
2. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing
3. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference
4. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
5. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome
6. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
7. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval
8. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial
9. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease
10. Anthera Enters Into Manufacturing Agreements for Varespladib in Preparation for Pivotal Phase III Trials
11. Anthera Announces Preliminary Positive Results From Once-Daily A-002 Phase II Cardiovascular Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... 2014   Health 2.0 announces Bernard Tyson ... physicians Eric Topol , Patrick Soon-Shiong , and ... 2.0 8th Annual Fall Conference this coming Sept. 21-24 ... Health 2.0 is set to host the very first Wearable ... on Consumer Tech & Wearables: Powering Healthy Lifestyles. ...
(Date:7/29/2014)... July 29, 2014   ... study investigating the efficacy and safety of MSB0010718C in patients ... a rare and aggressive skin cancer lacking effective treatments   ... cohort Phase I clinical trial for the treatment of solid ... EMD Serono, Inc., a subsidiary of Merck KGaA, Darmstadt, ...
(Date:7/28/2014)... July 28, 2014  Dignity Health St. Mary,s ... the Get With The Guidelines®-Stroke Silver-Plus Quality Achievement ... by the American Heart Association/American Stroke Association for ... number four cause of death and a leading ... United States , according to the American ...
Breaking Medicine Technology:Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 2Kaiser Permanente CEO to Keynote Health 2.0 8th Annual Fall Conference 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 2EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 3EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 4EMD Serono Initiates Phase II Study of Anti-PD-L1 Antibody MSB0010718C in Metastatic Merkel Cell Carcinoma 5Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 2Dignity Health St. Mary's Medical Center Honored with Quality Achievement Award for Stroke Care 3
... --Could Become First Effective Drug for Rare Genetic ... have used,a drug to achieve normal levels of ... high insulin levels. If this approach,succeeds in humans, ... congenital hyperinsulinism, a rare but potentially devastating genetic,disease ...
... First to Receive FDA, Clearance for Diagnosis of Uncertain Tumors; ... ... July 31 Pathwork Diagnostics, Inc.,a molecular diagnostics company focused on ... cleared its Pathwork(R),Tissue of Origin Test for use in determining the ...
Cached Medicine Technology:Treatment Corrects Severe Insulin Imbalance in Animal Studies 2Treatment Corrects Severe Insulin Imbalance in Animal Studies 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 2FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 3FDA Clears the Pathwork(R) Tissue of Origin Test for Hard-To-Identify Tumors 4
(Date:7/29/2014)... Mountain View, CA (PRWEB) July 29, 2014 ... officially released a new product called BNatrl Silver ... said Lis Herrey, CEO and spokesperson for BNatrl LLC. ... and your loved ones from harmful pathogens and microbes.” ... renewable energy, and clean water products, with 10 percent ...
(Date:7/29/2014)... Regents Health Resources, a consulting firm traditionally ... care industry veteran Daryl Demonbreun and former St. Thomas ... company’s ambitious plans to grow into a full-service health ... along at a steady pace for nearly 20 years, ... says Bob Maier, founder and chief executive officer of ...
(Date:7/29/2014)... (PRWEB) July 29, 2014 According ... Market by Type (Swipe And Area), Material (Optical ... Government, Defense, Healthcare, Commercial Security and Banking & ... to 2014 - 2020", published by MarketsandMarkets, the ... $14.35 Billion by 2020, growing at a high ...
(Date:7/29/2014)... This Latest Guidebook for Conducting Pharma Clinical ... not only provided a comprehensive and thorough knowledge of ... drug registration but also introduced the practical operation how ... to use the Chinese trial venues to keep drug ... by step. , The audiences of this guidebook are ...
(Date:7/29/2014)... There is controversy over how best to treat patients ... one wait until the cancer comes back or provide ... Now, a new study from Thomas Jefferson ... doctors and patients make a more informed decision. , ... says first author Robert Den, M.D., Assistant Professor of ...
Breaking Medicine News(10 mins):Health News:BNatrl Launches New Silver Solution Product 2Health News:Sferrella and Demonbruen Join Regents Health Resources 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Fingerprint Sensors Market by Type (Swipe And Area) Estimated to Reach $14.35 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 2Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 3Health News:Pharma Clinical Trials Market in China: Authorities for Drug New Study Now Available at MarketReportsOnline.com 4Health News:Genomic analysis of prostate cancer indicates best course of action after surgery 2
... LANSING, Mich., Dec. 30 Neogen Corporation,(Nasdaq: NEOG ) announces the ... Quarter Results Webcast, When: Tuesday, January 6, 2009 ... How: Live over the Internet -- Simply log on to ... above., Contact: Terry Maynard of Neogen ...
... for Nearly 20% of 45 plus PopulationCHICAGO, Dec. 30 ... be your health. According to a recent AARP ... are suffering health problems due to financial stress. ... many Americans are facing because of the current economic ...
... - Stubbing Out Your 5 a Day Habit ... , Leading Child Trust Fund provider, ... decide,to give up smoking as their New Year,s resolution to ... futures. , According to figures from ...
... New Year,s resolutions often include being more careful, ... behavior, such as drug use. But new research ... seekers by psychologists--face an uphill battle in keeping ... their brains process dopamine. The research reveals that ...
... Committee for Quality,Assurance and the American Diabetes Association ... Barnett, M.D., Mirela Sturzu,M.D., Rudolf Teschan, M.D., and ... Recognition Program for providing quality care to,patients with ... and Zaki practice at the Aurora Health Center, ...
... CORONA, Calif., Dec. 29 Watson Pharmaceuticals,Inc. (NYSE: ... and specialty branded pharmaceuticals,today announced that its subsidiary, ... United States Food and Drug Administration on its,Abbreviated ... estradiol tablets USP, 0.15 mg / 0.02 mg. ...
Cached Medicine News:Health News:Economic Stress Taking Toll on Peoples' Health 2Health News:Urging New Year Quitters to Invest in Their Family's Futures 2Health News:Risk takers, drug abusers driven by decreased ability to process dopamine 2Health News:Aurora Physicians Receive National Recognition for Quality Diabetes Care 2Health News:Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R) 2
... NEAR-SkinT™ Incise Drapes have aggressive ... permeability for extended adhesion. It's made ... for unsurpassed conformability with allow-glare matte ... identification. , ,Available sterile in ...
The Quantum II Dual Wavelength Analyzer measures differential absorbances of liquid samples and converts those readings into analytical values....
... The HYBrite Hybridization System - the hands-free ... Procedures. Now performing fluorescent in situ hybridization ... ever before. HYBrite is the first rapid, ... FISH procedures. Now you can have a ...
... CELL-DYN 4000 uses the power of ... parameters to the hematology laboratory. Fluorescent ... random-access reticulocyte results. Fluorescent DNA staining ... accurate white blood cell values and ...
Medicine Products: